AGREE REALTY CORP Overview
Industry: REIT Retail
Sector: Real Estate
Agree Realty Corporation is a publicly traded real estate investment trust that is RETHINKING RETAIL through the acquisition and development of properties net leased to industry-leading, omni-channel retail tenants. 1 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol "ADC". Agree Realty Corporation is a publicly traded real estate investment trust that is RETHINKING RETAIL through the acquisition and development of properties net leased to industry-leading, omni-channel retail tenants. 1 million square feet of gross leasable area. The Company's common stock is listed o Read MoreMavefund brings filings, fundamentals, valuation, price history and news for AGREE REALTY CORP into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Net income was $41M (-2% YoY). Adjusted EBITDA was $0.1M.
What changed
- Net income -2% YoY to $41M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
Headline from Yahoo Finance: U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs).
U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
Headline from Business Wire: U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs).
Agree Realty (ADC) Affirms Monthly Dividend, Is The 11% Undervaluation Case Convincing?
Headline from Yahoo Finance: Agree Realty (ADC) Affirms Monthly Dividend, Is The 11% Undervaluation Case Convincing?
ADC Therapeutics S.A. Q2 2026 Earnings Call Summary
Headline from Yahoo Finance: ADC Therapeutics S.A. Q2 2026 Earnings Call Summary.
ADC Therapeutics Q2 Earnings Call Highlights
Headline from Yahoo Finance: ADC Therapeutics Q2 Earnings Call Highlights.
ADC Therapeutics Q2 2026 slides: costs fall, FDA concerns weigh By Investing.com
Headline from Investing.com India: ADC Therapeutics Q2 2026 slides: costs fall, FDA concerns weigh By Investing.com.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.